false Q2 --03-31 2026 0001011060 0001011060 2025-04-01 2025-09-30 0001011060 2025-11-12 0001011060 2025-09-30 0001011060 2025-03-31 0001011060 NORD:SeriesAJuniorMember 2025-09-30 0001011060 NORD:SeriesAJuniorMember 2025-03-31 0001011060 NORD:PreferredStockUndesignatedMember 2025-09-30 0001011060 NORD:PreferredStockUndesignatedMember 2025-03-31 0001011060 2025-07-01 2025-09-30 0001011060 2024-07-01 2024-09-30 0001011060 2024-04-01 2024-09-30 0001011060 us-gaap:CommonStockMember 2025-03-31 0001011060 us-gaap:PreferredStockMember NORD:SeriesAJuniorMember 2025-03-31 0001011060 us-gaap:PreferredStockMember NORD:PreferredStockUndesignatedMember 2025-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001011060 us-gaap:RetainedEarningsMember 2025-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2025-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001011060 us-gaap:ParentMember 2025-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2025-03-31 0001011060 us-gaap:CommonStockMember 2025-06-30 0001011060 us-gaap:PreferredStockMember NORD:SeriesAJuniorMember 2025-06-30 0001011060 us-gaap:PreferredStockMember NORD:PreferredStockUndesignatedMember 2025-06-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001011060 us-gaap:RetainedEarningsMember 2025-06-30 0001011060 us-gaap:TreasuryStockCommonMember 2025-06-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001011060 us-gaap:ParentMember 2025-06-30 0001011060 us-gaap:NoncontrollingInterestMember 2025-06-30 0001011060 2025-06-30 0001011060 us-gaap:CommonStockMember 2024-03-31 0001011060 us-gaap:PreferredStockMember NORD:SeriesAJuniorMember 2024-03-31 0001011060 us-gaap:PreferredStockMember NORD:PreferredStockUndesignatedMember 2024-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001011060 us-gaap:RetainedEarningsMember 2024-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2024-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001011060 us-gaap:ParentMember 2024-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2024-03-31 0001011060 2024-03-31 0001011060 us-gaap:CommonStockMember 2024-06-30 0001011060 us-gaap:PreferredStockMember NORD:SeriesAJuniorMember 2024-06-30 0001011060 us-gaap:PreferredStockMember NORD:PreferredStockUndesignatedMember 2024-06-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001011060 us-gaap:RetainedEarningsMember 2024-06-30 0001011060 us-gaap:TreasuryStockCommonMember 2024-06-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001011060 us-gaap:ParentMember 2024-06-30 0001011060 us-gaap:NoncontrollingInterestMember 2024-06-30 0001011060 2024-06-30 0001011060 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001011060 us-gaap:PreferredStockMember NORD:SeriesAJuniorMember 2025-04-01 2025-06-30 0001011060 us-gaap:PreferredStockMember NORD:PreferredStockUndesignatedMember 2025-04-01 2025-06-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001011060 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001011060 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001011060 us-gaap:ParentMember 2025-04-01 2025-06-30 0001011060 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001011060 2025-04-01 2025-06-30 0001011060 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001011060 us-gaap:PreferredStockMember NORD:SeriesAJuniorMember 2025-07-01 2025-09-30 0001011060 us-gaap:PreferredStockMember NORD:PreferredStockUndesignatedMember 2025-07-01 2025-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001011060 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001011060 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001011060 us-gaap:ParentMember 2025-07-01 2025-09-30 0001011060 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0001011060 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001011060 us-gaap:PreferredStockMember NORD:SeriesAJuniorMember 2024-04-01 2024-06-30 0001011060 us-gaap:PreferredStockMember NORD:PreferredStockUndesignatedMember 2024-04-01 2024-06-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001011060 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001011060 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001011060 us-gaap:ParentMember 2024-04-01 2024-06-30 0001011060 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001011060 2024-04-01 2024-06-30 0001011060 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001011060 us-gaap:PreferredStockMember NORD:SeriesAJuniorMember 2024-07-01 2024-09-30 0001011060 us-gaap:PreferredStockMember NORD:PreferredStockUndesignatedMember 2024-07-01 2024-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001011060 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001011060 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001011060 us-gaap:ParentMember 2024-07-01 2024-09-30 0001011060 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001011060 us-gaap:CommonStockMember 2025-09-30 0001011060 us-gaap:PreferredStockMember NORD:SeriesAJuniorMember 2025-09-30 0001011060 us-gaap:PreferredStockMember NORD:PreferredStockUndesignatedMember 2025-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001011060 us-gaap:RetainedEarningsMember 2025-09-30 0001011060 us-gaap:TreasuryStockCommonMember 2025-09-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001011060 us-gaap:ParentMember 2025-09-30 0001011060 us-gaap:NoncontrollingInterestMember 2025-09-30 0001011060 us-gaap:CommonStockMember 2024-09-30 0001011060 us-gaap:PreferredStockMember NORD:SeriesAJuniorMember 2024-09-30 0001011060 us-gaap:PreferredStockMember NORD:PreferredStockUndesignatedMember 2024-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001011060 us-gaap:RetainedEarningsMember 2024-09-30 0001011060 us-gaap:TreasuryStockCommonMember 2024-09-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001011060 us-gaap:ParentMember 2024-09-30 0001011060 us-gaap:NoncontrollingInterestMember 2024-09-30 0001011060 2024-09-30 0001011060 NORD:AssetPurchaseAgreementMember 2020-01-31 2020-01-31 0001011060 NORD:ReddingtonPartnersLLCMember NORD:StockPurchaseAgreementMember 2021-10-12 2021-10-12 0001011060 NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-11 2022-03-11 0001011060 NORD:FirstClosingMember NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-11 2022-03-11 0001011060 NORD:ReddingtonPartnersLLCMember NORD:StockPurchaseAgreementMember NORD:SecondClosingMember 2022-03-15 2022-03-15 0001011060 NORD:ReddingtonPartnersLLCMember NORD:StockPurchaseAgreementMember 2022-03-15 0001011060 NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-15 2022-03-15 0001011060 NORD:ContributionAgreementMember 2023-02-23 2023-02-23 0001011060 NORD:ContributionAgreementMember 2023-02-23 0001011060 NORD:NordicusPartnersAsMember NORD:ContributionAgreementMember 2023-02-23 0001011060 NORD:MagMileCapitalIncMember 2023-06-01 0001011060 NORD:OrocidinASMember 2024-05-13 2024-05-13 0001011060 NORD:OrocidinASMember 2024-05-13 0001011060 NORD:StockPurchaseAgreementMember 2024-11-08 2024-11-08 0001011060 NORD:BioConvertASMember 2024-11-11 0001011060 NORD:BioConvertASMember 2024-11-11 2024-11-11 0001011060 NORD:OrocidinASMember 2024-11-12 2024-11-12 0001011060 NORD:OrocidinASMember 2024-11-12 0001011060 NORD:OrocidinASMember 2024-11-12 0001011060 NORD:DirectorsAgreementMember NORD:MuckeMember 2025-08-07 0001011060 NORD:DirectorsAgreementMember NORD:MessrsJensenMember 2025-08-07 0001011060 NORD:DirectorsAgreementMember NORD:MrRitterMember 2025-08-07 0001011060 NORD:DirectorsAgreementMember NORD:MuckeMember 2025-08-07 2025-08-07 0001011060 NORD:DirectorsAgreementMember NORD:MessrsJensenMember 2025-08-07 2025-08-07 0001011060 NORD:DirectorsAgreementMember NORD:MrRitterMember 2025-08-07 2025-08-07 0001011060 2024-11-08 2024-11-08 0001011060 2024-11-08 0001011060 us-gaap:WarrantMember 2025-04-01 2025-09-30 0001011060 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-09-30 0001011060 us-gaap:WarrantMember 2024-04-01 2024-09-30 0001011060 NORD:BioConvertMember 2025-01-01 2025-03-31 0001011060 NORD:BioConvertMember 2025-03-31 0001011060 2025-01-01 2025-03-31 0001011060 NORD:OrocidinASMember 2024-04-01 2025-03-31 0001011060 NORD:OrocidinASMember 2024-04-01 2024-06-30 0001011060 NORD:BioConvertASMember 2024-04-01 2025-03-31 0001011060 NORD:BioConvertASMember 2024-10-01 2024-12-31 0001011060 NORD:OrocidinASMember 2024-05-13 0001011060 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember 2025-10-01 2025-10-30 0001011060 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember 2025-10-30 0001011060 NORD:GKPartnersMember NORD:MagMileCapitalIncMember us-gaap:RestrictedStockMember 2023-06-19 2023-06-20 0001011060 NORD:GKPartnersMember us-gaap:RestrictedStockMember 2023-06-19 2023-06-20 0001011060 NORD:GKPartnersMember us-gaap:RestrictedStockMember 2023-06-20 0001011060 NORD:GKPartnersMember 2022-04-01 0001011060 NORD:GKPartnersMember 2023-12-22 0001011060 NORD:GKPartnersMember 2024-07-01 2024-09-30 0001011060 NORD:GKPartnersMember 2024-09-30 0001011060 NORD:GKPartnersMember 2024-12-30 0001011060 NORD:GKPartnersMember 2024-04-01 2025-03-31 0001011060 NORD:GKPartnersMember srt:MinimumMember 2025-03-31 0001011060 NORD:GKPartnersMember srt:MaximumMember 2025-03-31 0001011060 NORD:GKPartnersMember NORD:MagMileCapitalIncMember 2025-04-01 2025-09-30 0001011060 NORD:GKPartnersMember NORD:MagMileCapitalIncMember 2025-09-30 0001011060 NORD:MrBennettYankowitzMember 2025-07-01 2025-09-30 0001011060 NORD:MrBennettYankowitzMember 2024-07-01 2024-09-30 0001011060 NORD:MrBennettYankowitzMember 2025-04-01 2025-09-30 0001011060 NORD:MrBennettYankowitzMember 2024-04-01 2024-09-30 0001011060 NORD:MrBennettYankowitzMember 2025-09-30 0001011060 NORD:MrBennettYankowitzMember 2025-03-31 0001011060 NORD:HenrikRoufMember 2023-04-01 2023-04-01 0001011060 NORD:HenrikRoufMember 2024-04-08 2024-04-08 0001011060 NORD:HenrikRoufMember 2025-07-01 2025-07-01 0001011060 NORD:MrBennettYankowitzMember 2023-04-01 2023-04-01 0001011060 NORD:MrBennettYankowitzMember 2024-04-08 2024-04-08 0001011060 NORD:MrBennettYankowitzMember 2025-07-01 2025-07-01 0001011060 NORD:NpBioinnovationASMember 2023-02-23 0001011060 srt:BoardOfDirectorsChairmanMember 2024-06-03 2024-06-03 0001011060 srt:DirectorMember 2024-06-03 2024-06-03 0001011060 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-09-30 0001011060 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-09-30 0001011060 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-09-30 0001011060 us-gaap:FairValueMeasurementsRecurringMember 2025-09-30 0001011060 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0001011060 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-03-31 0001011060 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0001011060 us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001011060 us-gaap:PreferredStockMember 2025-09-30 0001011060 us-gaap:PreferredStockMember 2025-04-01 2025-09-30 0001011060 NORD:SeriesAJuniorMember 2025-04-01 2025-09-30 0001011060 NORD:PreferredStockUndesignatedMember 2025-09-30 0001011060 NORD:PreferredStockUndesignatedMember 2025-03-31 0001011060 NORD:PrivateInvestorsMember 2025-04-01 2025-09-30 0001011060 NORD:PrivateInvestorsMember srt:MinimumMember 2025-09-30 0001011060 NORD:PrivateInvestorsMember srt:MaximumMember 2025-09-30 0001011060 NORD:BoardOfDirectorsMember 2025-08-31 0001011060 2025-08-01 2025-08-31 0001011060 2024-06-07 0001011060 NORD:IncentiveStockOptionsMember 2024-06-07 0001011060 us-gaap:PerformanceSharesMember 2024-06-07 0001011060 us-gaap:EmployeeStockOptionMember 2025-09-30 0001011060 us-gaap:PerformanceSharesMember 2025-09-30 0001011060 NORD:ServiceSharesMember 2025-09-30 0001011060 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0001011060 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-09-30 0001011060 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001011060 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-09-30 0001011060 us-gaap:PerformanceSharesMember 2025-07-01 2025-09-30 0001011060 us-gaap:PerformanceSharesMember 2025-04-01 2025-09-30 0001011060 us-gaap:PerformanceSharesMember 2024-04-01 2025-03-31 0001011060 NORD:ThirdPartyMember 2024-04-01 2024-09-30 0001011060 2024-04-01 2025-03-31 0001011060 NORD:MonteCarloMember 2025-04-01 2025-09-30 0001011060 NORD:OrocidinASMember 2024-11-11 2024-11-11 0001011060 NORD:OrocidinASMember 2024-11-11 0001011060 NORD:OrocidinASMember 2025-03-31 0001011060 NORD:BioConvertASMember 2025-03-31 0001011060 NORD:OrocidinASMember 2025-04-01 2025-09-30 0001011060 NORD:BioConvertASMember 2025-04-01 2025-09-30 0001011060 NORD:OrocidinASMember 2025-09-30 0001011060 NORD:BioConvertASMember 2025-09-30 0001011060 us-gaap:WarrantMember 2025-03-31 0001011060 us-gaap:WarrantMember 2024-04-01 2025-03-31 0001011060 us-gaap:WarrantMember 2025-04-01 2025-09-30 0001011060 us-gaap:WarrantMember 2025-09-30 0001011060 us-gaap:SubsequentEventMember NORD:DarlingtonGroupLLCMember 2025-10-01 0001011060 srt:ScenarioForecastMember NORD:DarlingtonGroupLLCMember 2026-01-01 0001011060 srt:ScenarioForecastMember NORD:DarlingtonGroupLLCMember 2026-04-01 0001011060 srt:ScenarioForecastMember NORD:DarlingtonGroupLLCMember 2026-07-01 0001011060 us-gaap:SubsequentEventMember 2025-10-01 2025-10-01 0001011060 us-gaap:SubsequentEventMember 2025-10-01 0001011060 NORD:NoviTheraApsMember us-gaap:SubsequentEventMember 2025-10-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

☐

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 001-11737

NORDICUS PARTNERS CORPORATION

(Name of small business issuer in its charter)

Delaware

04-3186647

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

280 South Beverly Dr., Suite 505, Beverly Hills, CA		90212
(Address of principal executive offices)		(Zip Code)

Issuer’s telephone number (310) 666-0750

Securities registered under Section 12(b) of the Exchange Act:

None		None
Title of each class		Name of each exchange on which registered

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value per share

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	☐ Large Accelerated Filer	☐ Accelerated Filer
	☒ Non-accelerated Filer	☒ Smaller reporting company
	☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of November 12, 2025, there were 18,566,360 shares of the registrant’s Common Stock outstanding.

NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES

TABLE OF CONTENTS

		Page
PART I	FINANCIAL INFORMATION	3
Item 1	Unaudited Condensed Consolidated Financial Statements	3
	Condensed Consolidated Balance Sheets at September 30, 2025 (unaudited) and March 31, 2025	3
	Condensed Consolidated Statements of Operations and comprehensive income (loss) for the three and six months ended September 30, 2025 and 2024 (unaudited)	4
	Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended September 30, 2025 and 2024 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2025 and 2024 (unaudited)	6
	Notes to Condensed Consolidated Financial Statements (unaudited)	7
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3	Quantitative and Qualitative Disclosures About Market Risk	27
Item 4	Controls and Procedures	27
PART II	OTHER INFORMATION	28
Item 1.	Legal Proceedings	28
Item 1A.	Risk Factors	28
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3	Defaults Upon Senior Securities	28
Item 4	Mine Safety Disclosures	28
Item 5	Other Information	28
Item 6	Exhibits	28
	Signatures	29

PART I - FINANCIAL INFORMATION

Item 1. Unaudited Financial Statements

NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2025			March 31, 2025
	(unaudited)
ASSETS
Current assets:
Cash	$	242,155		$	19,914
Prepaid expenses and other current assets		242,199			37,656
Total current assets		484,354			57,570
In-process research and development		46,402,880			42,708,079
Property, Plant, and Equipment		7,730			—
Intangible assets		3,103			—
Goodwill		27,696,030			25,490,751
Investment in Mag Mile Capital, Inc.		1,250,000			1,925,000
Other assets		38,724			64,929
Total assets	$	75,882,821		$	70,246,329

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	1,006,875		$	1,062,661
Total current liabilities		1,006,875			1,062,661
Deferred tax liability		10,208,633			9,318,414
Total liabilities		11,215,508			10,381,075

Commitments and contingencies		—			—

Stockholders’ equity:
Preferred stock, Series A Junior; $0.001 par value; 500,000 shares authorized; no shares issued and outstanding		—			—
Preferred stock, undesignated; $0.001 par value; 4,500,000 shares authorized; no shares issued and outstanding		—			—
Preferred stock, value		—			—
Common Stock; $0.001 par value; 50,000,000 shares authorized; 18,399,002 and 17,252,502 shares issued and outstanding at September 30, 2025 and March 31, 2025, respectively		18,399			17,253
Treasury stock; 154 shares at cost		(30,328	)		(30,328	)
Additional paid-in capital		108,603,410			106,047,792
Accumulated other comprehensive income		5,579,040			615,385
Accumulated deficit		(49,503,208	)		(46,784,848	)
Total stockholders’ equity		64,667,313			59,865,254
Total liabilities and stockholders’ equity	$	75,882,821		$	70,246,329

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Unaudited)

	2025			2024			2025			2024
	For the three months ended						For the six months ended
	September 30,						September 30,
	2025			2024			2025			2024
Revenue	$	—		$	2,500		$	—		$	2,500

Operating expenses:
Officer compensation		285,398			49,104			350,752			98,546
Professional fees		119,192			46,428			396,963			72,210
Consulting expense		3,160			—			3,160			150,000
General and administrative		349,027			71,154			414,139			104,099
Research and development		454,701			343,209			878,350			343,209
Total operating expenses		1,211,478			509,895			2,043,364			768,064

Loss from operations		(1,211,478	)		(507,395	)		(2,043,364	)		(765,564	)

Other (expense) income:
Interest expense		4			(1	)		4			(1	)
Change in fair value of investment		(300,000	)		—			(675,000	)		—
Total other (expense) income		(299,996	)		(1	)		(674,996	)		(1	)

Loss before provision for income taxes		(1,511,474	)		(507,396	)		(2,718,360	)		(765,565	)
Provision for income tax		—			—			—			—
Net loss		(1,511,474	)		(507,396	)		(2,718,360	)		(765,565	)
Net loss attributable to noncontrolling interests		—			(6,611	)		—			(6,611	)
Net loss attributable to Nordicus Partners Corporation	$	(1,511,474	)	$	(500,785	)	$	(2,718,360	)	$	(758,954	)

Other comprehensive income (loss):
Foreign currency translation adjustment		(228,975	)		16,771			4,963,655			16,541
Comprehensive income (loss)	$	(1,740,449	)	$	(490,625	)	$	2,245,295		$	(749,024	)

Net loss per share attributable to Nordicus Partners Corporation - basic and diluted	$	(0.08	)	$	(0.10	)	$	(0.15	)	$	(0.19	)

Weighted average common shares outstanding - basic and diluted		17,877,902			4,960,079			17,583,155			4,050,313

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(Unaudited)

	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Stock			Income (Loss)			to Parent			Interest		Equity
	Common Stock				Preferred Stock, Series A Junior				Preferred Stock, Undesignated				Additional Paid-in		Accumulated			Treasury			Accumulated Other Comprehensive			Total Equity Attributed			Non-Controlling		Total Stockholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Stock			Income (Loss)			to Parent			Interest		Equity
Balance at March 31, 2025		17,252,502	$	17,253		—	$	—		—	$	—	$	106,047,792	$	(46,784,848	)	$	(30,328	)	$	615,385		$	59,865,254		$	—	$	59,865,254
Issuance of common stock		89,000		89		—		—		—		—		409,881		—			—			—			409,970			—		409,970
Foreign currency translation adjustment		—		—		—		—		—		—		—		—			—			5,192,630			5,192,630			—		5,192,630
Net loss		—		—		—		—		—		—		—		(1,206,886	)		—			—			(1,206,886	)		—		(1,206,886	)
Balance at June 30, 2025		17,341,502	$	17,342		—	$	—		—	$	—	$	106,457,673	$	(47,991,734	)	$	(30,328	)	$	5,808,015		$	64,260,968		$	—	$	64,260,968
Stock-based compensation		—		—		—		—		—		—		137,544		—			—			—			137,544			—		137,544
Issuance of common stock		1,057,500		1,057		—		—		—		—		2,008,193		—			—			—			2,009,250			—		2,009,250
Foreign currency translation adjustment		—		—		—		—		—		—		—		—			—			(228,975	)		(228,975	)		—		(228,975	)
Net loss		—		—		—		—		—		—		—		(1,511,474	)		—			—			(1,511,474	)		—		(1,511,474	)
Balance at September 30, 2025		18,399,002	$	18,399		—	$	—		—	$	—	$	108,603,410	$	(49,503,208	)	$	(30,328	)	$	5,579,040		$	64,667,313		$	—	$	64,667,313

	Common Stock				Preferred Stock, Series A Junior				Preferred Stock, Undesignated				Additional Paid-in		Accumulated			Treasury				Accumulated Other Comprehensive			Total Equity Attributed			Non-Controlling			Total Stockholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Stock				Income (Loss)			to Parent			Interest			Equity
Balance at March 31, 2024		1,110,226	$	1,110		—	$	—		—	$	—	$	45,696,761	$	(43,883,527	)	$	(30,328	)	$		(2,848	)	$	1,781,168		$	—		$	1,781,168
Common Stock issued in Orocidin business combination		3,800,000		3,800		—		—		—		—		18,996,200		—			—				—			19,000,000			—			19,000,000
Exercise of warrants		6,000		6		—		—		—		—		59,994		—			—				—			60,000			—			60,000
Common Stock issued for services		30,000		30		—		—		—		—		138,949		—			—				—			138,979			—			138,979
Forgiveness of debt - related party		—		—		—		—		—		—		13,886		—			—				—			13,886			—			13,886
Recognition of non-controlling interest in acquisition of Orocidin		—		—		—		—		—		—		—		—			—				—			—			450,000			450,000
Foreign currency translation adjustment		—		—		—		—		—		—		—		—			—				(230	)		(230	)		—			(230	)
Net loss		—		—		—		—		—		—		—		(258,169	)		—				—			(258,169	)		—			(258,169	)
Balance at June 30, 2024		4,946,226	$	4,946		—	$	—		—	$	—	$	64,905,790	$	(44,141,696	)	$	(30,328	)		$	(3,078	)	$	20,735,634		$	450,000		$	21,185,634
Balance		4,946,226	$	4,946		—	$	—		—	$	—	$	64,905,790	$	(44,141,696	)	$	(30,328	)		$	(3,078	)	$	20,735,634		$	450,000		$	21,185,634
Exercise of warrants		19,400		20		—		—		—		—		193,980		—			—				—			194,000			—			194,000
Orocidin issuance of common stock in capital raise		—		—		—		—		—		—		183,663		—			—				—			183,663			9,667			193,330
Foreign currency translation adjustment		—		—		—		—		—		—		—		—			—				16,771			16,771			—			16,771
Net loss		—		—		—		—		—		—		—		(500,785	)		—				—			(500,785	)		(6,611	)		(507,396	)
Balance at September 30, 2024		4,965,626	$	4,966		—	$	—		—	$	—	$	65,283,433	$	(44,642,481	)	$	(30,328	)		$	13,693		$	20,629,283		$	453,056		$	21,082,339
Balance		4,965,626	$	4,966		—	$	—		—	$	—	$	65,283,433	$	(44,642,481	)	$	(30,328	)		$	13,693		$	20,629,283		$	453,056		$	21,082,339

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	2025			2024
	For the six months ended
	September 30,
	2025			2024

Cash flows from operating activities:
Net loss	$	(2,718,360	)	$	(765,565	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		137,544			138,979
Change in fair value of investment		675,000			—
Amortization of website costs		215			—
Derecognition of deferred revenue upon consolidation of Orocidin A/S		—			(7,500	)
Changes in assets and liabilities:		—
Prepaid expenses and other current assets		(374,059	)		(42,431	)
Other assets		4,342			(41,424	)
Accounts payable and accrued expenses		47,107			110,570
Deferred revenue		(2,500	)		7,500
Foreign currency remeasurement		42,310			—
Net cash used in operating activities		(2,188,401	)		(599,871	)

Cash flows from investing activities:
Purchase of plant, property, and equipment		(10,844	)		—
Cash paid for website costs		—			(2,374	)
Cash acquired in business combinations		—			134,572
Net cash (used in) provided by investing activities		(10,844	)		132,198

Cash flows from financing activities:
Proceeds from issuance of common stock		2,419,220			193,330
Proceeds from exercise of warrants		—			254,000
Net cash provided by financing activities		2,419,220			447,330

Net change in cash		219,975			(20,343	)
Effect of exchange rate on cash		2,266			16,541
Cash at beginning of period		19,914			49,933
Cash at end of period	$	242,155		$	46,131

Supplemental disclosure of cash flow information:
Income taxes paid	$	—		$	—
Interest paid	$	—		$	—

Supplemental disclosures of non-cash information:
Common Stock issued for the acquisition of Orocidin	$	—		$	19,000,000
Forgiveness of debt - related party	$	—		$	13,866

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2025

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

Nordicus Partners Corporation (the “Company,” or “Nordicus” or “we”) was founded in 1993 as a subsidiary of PolyMedica Corporation. On January 31, 2020 (the “Closing Date”), we completed the sale of substantially all of our assets (the “Asset Sale”) for a total purchase price of $7,250,000 pursuant to an Asset Purchase Agreement entered into between us and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”). Prior to the Closing Date, we developed and manufactured advanced polymer materials which provided critical characteristics in the design and development of medical devices. Our biomaterials were marketed and sold to medical device manufacturers who used our advanced polymers in devices designed for treating a broad range of anatomical sites and disease states.

As a result of the Asset Sale, we ceased operating as a developer, manufacturer, marketer and seller of advanced polymers. Subsequent to the Closing Date, we became engaged in efforts to identify either an (i) operating company to acquire or merge with through an equity-based exchange transaction or (ii) investor interested in purchasing a majority interest in our Common Stock, whereby either transaction would likely result in a change in control.

On March 3, 2020, we filed a Certificate of Amendment to the Company’s Certificate of Incorporation. This amendment was unanimously approved by our Board of Directors, to change our name from AdvanSource Biomaterials Corporation to EKIMAS Corporation.

On October 12, 2021, we entered into a Stock Purchase Agreement (the “SPA”) with Reddington Partners LLC, a California limited liability company (“Reddington”) providing for the purchase of a total of 511,448 shares of our Common Stock, on a post-split basis, or approximately 90% of our total shares of Common Stock outstanding, for total cash consideration of $400,000. Reddington purchased the Common Stock in two tranches on October 12, 2021 and March 15, 2022.

Pursuant to the SPA, the Company effectuated a 1-for 50 reverse stock split on March 11, 2022. Accordingly, on a post-split basis, the shares purchased in connection with the First Closing resulted in Reddington owning 42,273 shares of our Common Stock. As set forth in the SPA, Reddington then purchased from us on March 15, 2022, an additional 469,175 shares of our Common Stock, on a post-split basis (the “Second Closing”). After the issuance thereof, Reddington owned 511,448 shares of our Common Stock, or approximately 90% of our total shares of Common Stock outstanding.

On February 23, 2023, the Company and NP Bioinnovation A/S (formerly Nordicus Partners A/S and Managementselskabet af 12.08.2020 A/S), a Danish stock corporation, consummated the transactions contemplated by a certain contribution agreement (the “Contribution Agreement”) by and among the Company, NP Bioinnovation A/S, GK Partners ApS (“GK Partners”), Henrik Rouf and Life Science Power House ApS (“LSPH”) (GK Partners, Rouf and LSPH are collectively referred to herein as the “Sellers”, and each individually as a “Seller”). Pursuant to the Contribution Agreement the Sellers contributed, transferred, assigned and conveyed to the Company all right, title and interest in and to one hundred percent (100%) of the issued and outstanding capital stock of NP Bioinnovation A/S for an aggregate of 250,000 shares of the Company’s Common Stock, par value $0.001 per share. As a result of this transaction, NP Bioinnovation A/S became a 100% wholly owned subsidiary of the Company.

On February 23, 2023, Tom Glaesner Larsen and Christian Hill-Madsen were appointed directors of the Company.

On May 17, 2023, the Company changed its name to Nordicus Partners Corporation and its ticker symbol to NORD.

On June 1, 2023, the Company acquired a 4.99% interest in Mag Mile Capital, Inc. (“Mag Mile Capital”), a full-service commercial real estate mortgage banking firm headquartered in Chicago with offices in the states of New York, Massachusetts, Connecticut, Florida, Texas and Nevada. Mag Mile Capital is a national platform comprised of capital markets specialists with extensive experience in real estate bridge financing, mezzanine and permanent debt placement and equity arrangements throughout the full capital stack and across all major real estate asset classes nationwide, including hotels, multifamily, office, retail, industrial, healthcare, self-storage and special purpose properties, offering access to structured debt and equity advisory solutions and placement for real estate investors, developers, and entrepreneurs.

On June 9, 2023, Tom Glaesner Larsen resigned from the Company’s Board of Directors, and the remaining board members appointed Henrik Keller as his replacement.

On November 29, 2023, the Company’s subsidiary, Nordicus Partners A/S, changed its name to Managementselskabet af 12.08.2020 A/S. Subsequently on March 10, 2025, Managementselskabet af 12.08.2020 A/S changed its name to NP Bioinnovation A/S.

On May 13, 2024, the Company and certain shareholders of Orocidin A/S (the “Orocidin Sellers”), a Danish stock corporation (“Orocidin”), entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Orocidin Sellers sold to the Company 525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing 95.0% of Orocidin’s outstanding shares of capital stock. In exchange, the Company issued 3,800,000 restricted shares of its Common Stock to the Orocidin Sellers. The transaction was consummated on May 13, 2024. Orocidin A/S, is a preclinical-stage biotechnology company which is advancing the next generation of periodontitis therapies.

On June 3, 2024, Mr. Christian Hill-Madsen resigned as a director of the Company and Peter Severin was appointed as his replacement.

On November 8, 2024, the Company effected a 1:10 reverse stock split of its Common Stock.

On November 11, 2024, the Company announced that it entered into an agreement with Bio-Convert A/S (“Bio-Convert”) to acquire 100% of the outstanding shares of Bio-Convert in exchange for 12,000,000 restricted shares of the Company’s Common Stock. Bio-Convert is a Denmark-based preclinical-stage biotechnology company aiming to revolutionize the treatment of oral leukoplakia by minimizing or removing oral leukoplakia lesions in order to further reduce the risk of such lesions resulting in the development of oral cancer in patients.

On November 12, 2024, the Company entered into an agreement with Orocidin A/S to acquire the remaining 29,663 outstanding shares, or approximately 5%, of Orocidin A/S. In exchange, the Company issued 200,000 shares of restricted Common Stock to the selling shareholders of Orocidin. Upon closing of the acquisition, Orocidin A/S became a 100% wholly owned subsidiary of the Company.

On August 7, 2025, (1) Henrik Keller resigned from the Board of Directors of the Company, (2) the Board increased its size from three to five members and (3) appointed Torben S. Jensen, Kim T. Mücke and Andrew J. Ritter to fill the resulting vacancies. On August 7, 2025, the Company executed a Directors Agreement with each of Messrs. Jensen, Mücke and Ritter. Under the Director’s Agreements, each will receive an annual cash retainer of $10,000, payable in two installments per calendar year, in accordance with the Company’s standard compensation plan for Board members. Messrs. Jensen and Mücke will also each receive options to purchase 25,000 shares of the Company’s common stock at $1.90 per share, and Mr. Ritter will receive options to purchase 50,000 shares of the Company’s common stock at $1.90 per share. All such options will be fully vested on the date of grant and be issued as Incentive Stock Options under and be subject to the terms and conditions of, the Company’s 2024 Stock Incentive Plan.

In October 2005, the Company formed a new subsidiary named NoviThera Aps, with the objective to research and develop a novel and unique Monoclonal antibody (MaB) as a novel innovative therapy for the treatment of psoriasis. The invention was made by Alteral Therapeutics in Denmark and the drug development acquired by NoviThera. Mr. Allan Wehnert, who controls Alteral Therapeutics, was appointed CEO of NoviThera.

Description of Business

Since the current leadership assumed control of Nordicus, the Company has evolved into a business accelerator and holding company dedicated to helping Nordic life sciences companies succeed in the American market. By combining Nordic innovation with U.S. operational expertise, the Company endeavors to create a distinct advantage in identifying, scaling, and exiting high-potential companies in fast-growing markets with unmet medical needs. Nordicus’ mission is to back high-growth ventures and transformative innovations in the life sciences sector. Nordicus’ portfolio diversification strategy aims to positions it as a stable and resilient company, mitigating risk with significant upside potential.

Nordicus’ current life sciences portfolio consists of three preclinical biotechnology companies in Orocidin A/S, Bio-Convert A/S and NoviThera ApS led by the accomplished pharmacologist, Allan Wehnert, who serves as CEO of all three companies.

Orocidin A/S is developing a proprietary first-of-its-kind medical treatment for aggressive periodontitis. Most recently, Orocidin A/S successfully completed a 14-day toxicology study in hamsters and a test of effectiveness in a Beagle Dog Study, respectively.

Bio-Convert A/S is focused on a treatment against oral leukoplakia (OLK) – an oral potentially malignant disorder – by developing a novel proprietary mucoadhesive oral topical formulation designed to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia. Most recently, Bio-Convert A/S received positive and constructive scientific advice from the Danish Medicines Agency (DKMA) regarding its lead candidate, QR-02, as a treatment for oral leukoplakia.

NoviThera ApS was formed to research and develop a novel and unique Monoclonal antibody (MaB) as a novel innovative therapy for the treatment of psoriasis

The companies’ innovative breakthroughs are further strengthened by their oral formulations ensuring prolonged adhesion for 12-24 hours and controlled release of the active ingredient, enhancing drug efficacy and patients’ outcomes – a major advancement over normal gels and creams.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the six months ended September 30, 2025 and 2024, and not necessarily indicative of the results to be expected for the full year ending March 31, 2026. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025.

Reverse Stock Split

On November 8, 2024, the Company effectuated a 1-for-10 reverse stock split of its issued and outstanding Common Stock, rounding up to account for any fractional shares. The reverse stock split had no effect on the Company’s authorized shares of Common Stock or Preferred Stock and the par value of both remained unchanged at $0.001. All Common Stock share, warrant and per share amounts (except our authorized but unissued shares) have been retroactively adjusted in these unaudited condensed consolidated financial statements and related disclosures.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s accounting estimates include the useful lives of long-lived assets and recoverability of those assets, impairment in fair value of goodwill, and the fair value of assets acquired and liabilities assumed in business combinations.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. The Company also maintains cash in foreign bank accounts that are not federally insured. The Company continually monitors its banking relationships and consequently have not experienced any losses in its accounts. The Company believes it is not exposed to any significant credit risk on cash.

Cash and Cash Equivalents

Cash amounts include cash on hand and cash on deposit with banks. The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of September 30, 2025 and March 31, 2025.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, NP Bioinnovation A/S, Orocidin A/S, and Bio-Convert A/S. All significant intercompany transactions have been eliminated in consolidation.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation and used by chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s Chief operating decision-maker (“CODM”), the Company’s chief executive officer, view the Company’s operations and manages its business as a single operating segment. See Note 12 for more information.

Translation Adjustment

The reporting currency of the Company is U.S. Dollars. The accounts of the Company’s subsidiaries are maintained in Danish krone. According to Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Matters, all assets and liabilities were translated at the current exchange rate at respective balance sheets dates, stockholders’ equity transactions are translated at the historical rates and statement of operations accounts are translated at the average exchange rate for the period. The resulting translation adjustments are reported in other comprehensive income (loss) in accordance with ASC Topic 220, Reporting Comprehensive Income (“ASC 220”) in the unaudited condensed consolidated statements of operations and in accumulated other comprehensive income (loss) as a component of stockholders’ equity.

Comprehensive Income (Loss)

Comprehensive income (loss) is comprised of net loss and all changes to the unaudited condensed consolidated statements of stockholders’ equity, except changes in paid-in capital and distributions to shareholders. Comprehensive income (loss) is inclusive of net loss and foreign currency translation adjustments.

Research and Development Costs

Research and development costs consists primarily of costs associated with Orocidin and Bio-Convert’s ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.

Stock-based Compensation

The Company accounts for stock-based compensation using the provisions of ASC Topic 718, Stock Compensation, which requires the recognition of the fair value of stock-based compensation. Stock-based compensation is estimated at the grant date based on the fair value of the awards. The Company accounts for forfeitures as they occur. Compensation cost for service awards is recognized using the straight-line method over the vesting period. Compensation cost for performance awards is recognized when the vesting condition becomes probable of occurring. Stock-based compensation is included in officer compensation, general and administrative, research and development, and consulting expense in the unaudited condensed consolidated statements of operations and comprehensive loss.

Investments

The Company accounts for its investment under the guidance of ASC Topic 321, Investments – Equity Securities, which provides guidance for equity interests that meet the definition of an equity security. Equity interests with readily determinable fair values are carried at fair value with changes in value recorded in earnings. Investments without readily determinable fair values are accounted for using the measurement alternative which is at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

Fair Value of Financial Instruments

The Company follows paragraph 825-10-50-10 of the FASB ASC for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB ASC (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:

Level 1:	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
Level 2:	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
Level 3:	Pricing inputs that are generally unobservable inputs and not corroborated by market data.

The carrying amount of the Company’s financial assets and liabilities, such as cash, prepaid expenses, accounts payable and accrued expenses approximate their fair value because of the short maturity of those instruments.

Distinguishing Liabilities from Equity

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in the FASB ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Topic 815, Derivatives and Hedging. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC Topic 480, meet the definition of a liability pursuant to ASC Topic 480, and whether the warrants meet all of the requirements for equity classification under ASC Topic 815, including whether the warrants are indexed to the Company’s Common Stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and on the date of issuance and for liability-classified awards, remeasured to fair value at each balance sheet date thereafter.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized in change in fair value of warrant liabilities in the unaudited condensed consolidated statements of operations and comprehensive income (loss).

Net Loss per Share

Net loss per share is computed pursuant to ASC Topic 260, Earnings Per Share. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of shares of Common Stock and potentially outstanding shares of Common Stock during the period. As of September 30, 2025, there were 1,000,000 potentially dilutive shares of Common Stock from 75,000 equity-classified warrants and 925,000 stock options. As of September 30, 2024, there were 60,750 potentially dilutive shares of common stock from equity-classified warrants. Diluted shares are not presented when the effect of the computations is anti-dilutive due to the losses incurred. Accordingly, there is no difference in the amounts presented for basic and diluted loss per share.

Business Combinations

The Company accounts for business combinations under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations, where the total purchase price is allocated to the tangible and identified intangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The purchase price is allocated using the information currently available, and may be adjusted, up to one year from acquisition date, after obtaining more information regarding, among other things, asset valuations, liabilities assumed and revisions to preliminary estimates. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill. Identifiable intangible assets with finite lives are amortized over their useful lives. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which the costs are incurred. The results of operations of acquired businesses are included in the unaudited condensed consolidated financial statements from the acquisition date.

Purchase Accounting Measurement Period Adjustments

From time to time, the Company makes acquisitions accounted for as business combinations under ASC 805. Certain asset and liability values are initially recorded as provisional and may be adjusted during the measurement period as new information becomes available. Finalized valuations result in retrospective adjustments to reflect facts and circumstances that existed at the acquisition date.

During the quarter ended March 31, 2025, the Company completed its determination of the fair values of purchase consideration for Bio-Convert, inclusive of non-cash consideration paid by the Company and in-process research and development. The measurement period adjustment resulted in (i) a 26,475,819 increase in in-process research and development recorded and (ii) recognition of a $5,868,647 deferred tax liability associated with the in-process research and development asset. The net effect of such measurement period adjustments was recorded as an adjustment to goodwill.

During the quarter ended March 31, 2025, the Company completed its determination of the fair values of purchase consideration, inclusive of non-cash consideration paid by the Company and the fair value of non-controlling interest, and in-process research and development. The measurement period adjustment resulted in (i) a $450,000 net increase in total consideration paid, (ii) a $15,457,444 increase in in-process research and development recorded, and (iii) recognition of a $3,449,767 deferred tax liability associated with the in-process research and development asset. The net effect of such measurement period adjustments was recorded as an adjustment to goodwill.

Goodwill

The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing the Company’s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of any of the Company’s reporting units is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of any of the reporting units is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.

The Company assesses goodwill for impairment on an annual basis as of March 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired. The Company did not record an impairment charge during the three and six months ended September 30, 2025 and 2024.

Indefinite-lived Intangible Assets

The Company accounts for its indefinite-lived intangible assets in accordance with ASC Topic 350, Intangibles - Goodwill and Other (“ASC 350”). Indefinite-lived intangible assets are not amortized but instead are reviewed for impairment annually, or more frequently if an event occurs or circumstances change which indicate that an asset might be impaired. Pursuant to ASC 350, the Company tests its indefinite-lived intangible assets, which consist of certain in-process research and development (IPR&D) assets acquired via the Company’s business combinations with Orocidin A/S and Bio-Convert A/S detailed in Note 10, for impairment by comparing their fair values to their carrying values. An impairment charge is recorded if the estimated fair value of such assets has decreased below their carrying values. The Company did not record an impairment charge during the three and six months ended September 30, 2025 and 2024.

Revenue Recognition

The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company determines revenue recognition through the following steps:

	●	Identification of a contract with a customer;
	●	Identification of the performance obligations in the contract;
	●	Determination of the transaction price;
	●	Allocation of the transaction price to the performance obligations in the contract; and
	●	Recognition of revenue when or as the performance obligations are satisfied.

In January 2024, the Company signed an agreement with Orocidin for which it recognized $2,500 in revenue during the year ended March 31, 2025. Since Orocidin became a subsidiary in the quarter ended June 30, 2024, no more revenue is to be recognized under this agreement, but is eliminated as an intercompany transaction.

In June 2024, the Company signed an agreement with Bio-Convert for which it recognized $2,500 in revenue during the year ended March 31, 2025. Since Bio-Convert became a subsidiary in the quarter ended December 31, 2024, no more revenue is to be recognized under this agreement, but is eliminated as an intercompany transaction.

Non-controlling Interests

In accordance with ASC Topic 810, Consolidation (“ASC 810”), the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE.

If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary.

Following the acquisition of 95% of Orocidin A/S in May 2024, the Company determined that Orocidin A/S was a VIE, and that the Company was the primary beneficiary. While the Company owned 95% of Orocidin A/S’s equity interests, the remaining equity interests in Orocidin A/S were owned by unrelated third parties, and the agreement with these third parties provided the Company with greater voting rights. Accordingly, the Company consolidated its interest in Orocidin A/S under the VIE rules and reflected the third parties’ interests in the condensed consolidated financial statements as a non-controlling interest. The Company recorded this non-controlling interest at its initial fair value, adjusting the basis prospectively for the third parties’ share of the respective consolidated investments’ net income or loss or equity contributions and distributions. These non-controlling interests were not redeemable by the equity holders and were presented as part of permanent equity. Income and losses were allocated to the non-controlling interest holders based on its economic ownership percentage. Transactions with non-controlling interests that do not result in a loss of control are accounted for as equity transactions. Any difference between the fair value of the consideration paid or received and the carrying amount of the non-controlling interest is recognized in equity.

In November 2024, the Company acquired the remaining 5% interest in Orocidin A/S. As a result, Orocdin A/S became a wholly owned subsidiary and was no longer considered a VIE. The noncontrolling interest in Orocidin was derecognized from the Company’s condensed consolidated financial statements at the time of the acquisition of the remaining 5% interest.

Risks and Uncertainties

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of research and development, clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company’s products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.

Recently Issued Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. This Update enhances the transparency and usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. The guidance also eliminates certain existing requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in this Update are effective for annual periods beginning after December 15, 2024. Early adoption of the amendments is permitted for annual financial statements that have not yet been issued. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements and anticipates reflecting the impact of adoption in its annual financial statements for the year ended March 31, 2026.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“DISE”), which will require additional disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. This ASU was further clarified by ASU 2025-01, Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures, Disaggregation of Income Statement Expenses, which was issued in December 2024. The new standards require disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The new standards will be effective for public companies for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company is currently evaluating the impact of these accounting standard updates on its financial statements.

The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 3 - GOING CONCERN

The Company’s unaudited condensed consolidated financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has recognized nominal revenue and has incurred losses since inception resulting in an accumulated deficit of $49,503,208 and held cash of $242,155 as of September 30, 2025. As a result, the Company’s current funds will not be sufficient to meet its needs for more than twelve months from the date of issuance of these unaudited condensed consolidated financial statements. Accordingly, there is substantial doubt about the ability to continue as a going concern.

The ability to continue as a going concern is dependent upon the Company’s recent acquisitions, its generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and through private placements of Common Stock. In October 2025, the Company issued to certain private investors a total of 225,000 restricted shares of its common stock, par value $0.001 per share. The price per share was $2.75 for gross proceeds of $618,750. The unaudited condensed consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

NOTE 4 - INVESTMENTS

On June 20, 2023, the Company and GK Partners ApS entered into a Stock Purchase and Sale Agreement, under which GK Partners ApS sold to the Company 5,000,000 restricted shares of common stock of Mag Mile Capital, Inc. (“Mag Mile”). The shares were restricted in that they were subject to a registration statement being filed on Form S-1 by Mag Mile on September 6, 2023. The Form S-1 became effective on July 5, 2024, removing the restriction on the shares. In exchange, the Company issued 250,000 restricted shares of its Common Stock to GK Partners ApS. The shares were valued at $1,750,000, at a price of $7.00 per share, the closing stock price for the Company’s Common stock on the last business day before the agreement.

There is an active market for the shares of Mag Mile as of September 30, 2025. Therefore, the investment had an observable change in the value of Mag Mile’s shares that can be used to adjust the value of the Company’s investment in those shares. During the three and six months ended September 30, 2025, the Company observed price changes to the trading price per share of Mag Mile’s common stock and recorded a decrease of $300,000 and $675,000, respectively in the Company’s investment.

NOTE 5 - RELATED PARTY TRANSACTIONS

Mr. Tom Glasner Larsen is the spouse of Mrs. Glaesner, CEO of GK Partners, and was a member of our board of directors from February 23, 2023 until his voluntary retirement on June 9, 2023. He was a beneficial owner of a controlling interest in NP Bioinnovation A/S (formerly Managementselskabet af 12.08.2020 A/S) until its acquisition by the Company on February 23, 2023. He was also a beneficial owner of a controlling interest in Orocidin A/S until its acquisition by the Company on May 13, 2024, and a beneficial owner of a controlling interest in Bio-Convert A/S until its acquisition by the Company on November 11, 2024.

Effective April 1, 2022, we issued to GK Partners, for financial services, a warrant (the “2022 GK Warrant”) to purchase up to 600,000 shares of our Common Stock at an exercise price of $10.00 per share, and which had an expiration date of December 31, 2023. The Company determined that the 2022 GK Warrant was not precluded from equity classification and was therefore recorded within additional paid-in capital on the Company’s consolidated balance sheets at its issuance date fair value. On December 22, 2023, the expiration date of the warrant, covering 570,500 remaining unexercised warrant shares, was extended to December 31, 2024. During the quarter ended September 30, 2024, GK Partners exercised a portion of its warrant for 19,400 shares. The exercise price was $10.00 per share for total proceeds of $194,000. On December 31, 2024 the 2022 GK Warrant expired.

Effective December 30, 2024, warrants were issued to GK Partners (the “2024 GK Warrant”) to purchase up to 1,000,000 shares of the Company’s Common Stock at an exercise price equal to the greater of $8.91 and the daily volume weighted average price of the Common Stock for the ten trading days immediately preceding the date of exercise. The 2024 GK Warrant was scheduled to expire on December 31, 2025. The Company determined that the 2024 GK Warrant was precluded from being classified within equity and was liability classified under ASC Topic 815, Derivatives and Hedging. During the year ended March 31, 2025, GK Partners exercised a portion of its 2024 GK Warrant for a total of 35,176 shares. The exercise price ranged from $8.91 to $8.95 per share for total proceeds of $313,455. On March 31, 2025, the 2024 GK Warrant was terminated. Immediately prior to the termination, the fair value of the 2024 GK Warrant was $167,000, which was reclassified to additional paid in capital due to the related party relationship with GK Partners.

As detailed in Note 4, on June 20, 2023, the Company and GK Partners entered into a Stock Purchase and Sale Agreement whereby the Company acquired equity interests in Mag Mile.

During the six months ended September 30, 2025, GK Partners purchased 49,000 shares of the Company’s common stock at a price of $5.00 per share for gross proceeds of $245,000.

Mr. Bennett Yankowitz, our chief financial officer and director, was affiliated with legal counsel who provided us with general legal services (the “Affiliate”). We recorded legal fees to the Affiliate of $15,198 and $20,852 for the three months ended September 30, 2025 and 2024, respectively, and $16,492 and $38,634 for the six months ended September 30, 2025 and 2024, respectively. As of September 30, 2025 and March 31, 2025, we had no outstanding payables due to the Affiliate for either period.

Our employment agreement with Henrik Rouf, our chief executive officer, provided for a base salary of $72,000 per year, commencing April 1, 2023, and had a term of one year. On April 8, 2024 the agreement was amended to increase Mr. Rouf’s annual salary to $120,000 and to extend the term to April 1, 2025. On July 1, 2025 the agreement was amended to increase Mr. Rouf’s annual salary to $360,000 and to extend the term to July 1, 2026.

Our consulting agreement with Bennett Yankowitz, our chief financial officer and a member of our board of directors, provided for a base salary of $36,000 per year, commencing April 1, 2023, and had a term of one year. On April 8, 2024 the agreement was amended to increase Mr. Yankowitz’s annual salary to $60,000 and to extend the term to April 1, 2025. On July 1, 2025 the agreement was amended to increase Mr. Yankowitz’s annual salary to $120,000 and to extend the term to July 1, 2026.

During the six months ended September 30, 2024, a related party forgave their payable of $13,886. The amount has been credited to additional paid in capital.

Effective June 3, 2024, Christian Hill-Madsen resigned from the Board of Directors of the Company, and the remaining Board members appointed Peter Severin as his replacement and as Chairman of the Board of Directors. Mr. Hill-Madsen will continue as CEO of NP Bioinnovation A/S, of which the Company acquired 100% of the outstanding shares in exchange for shares of the Company on February 23, 2023.

On June 3, 2024, the Company’s Board of Directors approved a compensation plan under which the Chairman of the Board of Directors will receive compensation of $20,000 per annum, and each other Director will receive compensation of $10,000 per annum, in consideration of their serving on the Corporation’s Board of Directors, payable in equal installments semiannually in arrears, commencing December 31, 2024, without proration for partial terms.

NOTE 6 - FAIR VALUE MEASUREMENTS

The following tables provide information related to the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2025 and March 31, 2025:

	Level 1		Level 2		Level 3		Total
	September 30, 2025
	Level 1		Level 2		Level 3		Total
Assets:
Investment in Mag Mile Capital, Inc.	$	1,250,000	$	—	$	—	$	1,250,000
Assets	$	1,250,000	$	—	$	—	$	1,250,000

	Level 1		Level 2		Level 3		Total
	March 31, 2025
	Level 1		Level 2		Level 3		Total
Assets:
Investment in Mag Mile Capital, Inc.	$	1,925,000	$	—	$	—	$	1,925,000
Assets	$	1,925,000	$	—	$	—	$	1,925,000

NOTE 7 - PREFERRED STOCK

Preferred Stock

We have authorized 5,000,000 shares, $0.001 par value, preferred stock (the “Preferred Stock”) of which 500,000 shares have been issued and redeemed, and therefore are not considered outstanding. In addition, 500,000 shares of Preferred Stock have been designated as Series A Junior Participating Preferred Stock (the “Junior Preferred Stock”) with the designations and the powers, preferences, rights, qualifications, limitations and restrictions specified in the Certificate of Designation of the Junior Preferred Stock filed with the Delaware Department of State on January 28, 2008. Such number of shares may be increased or decreased by resolution of the Board of Directors, provided that no decrease shall reduce the number of shares of Junior Preferred Stock to a number less than the number of shares then outstanding plus the number of shares reserved for issuance upon the exercise of outstanding options, rights or warrants or upon the conversion of any outstanding securities issued by the Company that are convertible into Junior Preferred Stock. Each share of Junior Preferred Stock shall entitle the holder to 100 votes on all matters submitted to a vote of the Company’s stockholders. The holders of shares of Junior Preferred Stock, in preference to the holders of the Company’s Common Stock and of any other junior stock, shall be entitled to receive, when and if declared by the Board of Directors out of funds legally available for the purpose, quarterly dividends payable in cash. Upon the Company’s liquidation, dissolution or winding up, no distribution shall be made to the holders of shares of stock ranking junior to the Junior Preferred Stock unless, prior thereto, the holders of shares of Junior Preferred Stock shall have received $100 per share, plus an amount equal to accrued and unpaid dividends and distributions thereon. The Junior Preferred Stock shall rank, with respect to the payment of dividends and the distribution of assets, junior to all series of any other class of Preferred Stock. As of September 30, 2025 and March 31, 2025, there are no shares of Junior Preferred Stock or undesignated Preferred Stock issued and outstanding.

NOTE 8 - COMMON STOCK TRANSACTIONS

The Company is authorized to issue 50,000,000 shares of common stock with a par value of $0.001 per share (the “Common Stock”). Holders of the Company’s Common Stock are entitled to one vote for each share.

During the six months ended September 30, 2025, the Company issued 1,146,500 shares of Common Stock to private investors. The purchase price ranged from $1.90-5.00 per share, resulting in total net proceeds of $2,419,220.

In August 2025, the Company’s Board of Directors authorized a share repurchase program which permits the Company to repurchase up to an aggregate of 200,000 shares of the Company’s Common Stock from existing shareholders only, solely in privately negotiated transactions, at a purchase price per share not greater than the then-current market price as determined based on the last reported sale price of the Company’s Common Stock on the Company’s principal trading market. The Company is not obligated to repurchase any shares and may suspend or terminate the program at any time. Repurchased shares may be held as treasury stock or retired, as determined by the Company. The repurchase program will remain in effect until the earliest of (i) the repurchase of 200,000 shares, (ii) 12 months from the date the program was authorized, or (iii) revocation by further Board action. As of September 30, 2025, no share repurchases had closed.

NOTE 9 - STOCK-BASED COMPENSATION

In June 2024, the Company established the Nordicus Partners Corporation 2024 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to promote the long-term growth and profitability of the Company by (i) providing key people with incentives to improve stockholder value and to contribute to the growth and financial success of the Company, and (ii) enabling the Company to attract, retain and reward the best-available persons.

The Plan permits the granting of stock options (including incentive stock options qualifying under Code Section 422 and nonqualified stock options), stock appreciation rights (SARs), restricted or unrestricted stock awards, restricted stock units, performance awards, other stock-based awards, or any combination of the foregoing.

Participation in the Plan shall be open to all employees, officers, directors, and consultants of the Company, or of any affiliate of the Company, as may be selected by the Company from time to time. However, only employees of the Company, and of any parent or subsidiary of the Company, shall be eligible for the grant of an incentive stock option. The grant of an award at any time to any person shall not entitle that person to a grant of an award at any future time.

The shares of Common Stock that may be issued with respect to awards granted under the Plan shall not exceed an aggregate of 7,000,000 shares of Common Stock. The maximum number of shares of Common Stock under the Plan that may be issued as incentive stock options shall be 7,000,000 shares. Regarding performance-based award limitations, the number of shares of Common Stock that may be granted in the form of options, SARs, restricted stock awards, restricted stock units, or performance award shares in a single fiscal year to a participant may not exceed 2,000,000 of each form.

The following table summarizes the Company’s stock option activity under the Plan for the six months ended September 30, 2025. Included in the 925,000 outstanding options are 375,000 performance-based awards and 550,000 service-based awards:

SCHEDULE OF STOCK OPTION

	Number of Stock Options		Weighted-average Exercise Price per Option*		Weighted-average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding as of March 31, 2025		825,000	$	3.25		9.63		675,000
Granted		100,000	$	1.90		—		—
Outstanding as of September 30, 2025		925,000	$	3.00		9.70		960,000
Exercisable and vested as of September 30, 2025		550,000	$	3.00		9.70		960,000

The weighted-average exercise price excludes the exercise price for the performance awards due to the variable nature of the exercise price. See below for more discussion of the performance awards.

The stock-based compensation expense related to option grants under the Plan was $137,544 for the three and six months ended September 30, 2025 and 2024 and was recognized within officer compensation on the Company’s consolidated statement of operations and comprehensive loss.

All of the service based awards in the table above were fully vested at issuance and therefore all related compensation expense was recognized prior to and during the six months ended September 30, 2025. There was no unrecognized compensation cost related to the service based options as of September 30, 2025. The Performance Awards in the table above will fully vest when the vesting terms are met and expense will be recognized when the vesting event becomes probable. Therefore, no stock-based compensation expense was recorded for the three and six months ended September 30, 2025.

During the year ended March 31, 2025, 375,000 performance awards (the “Performance Awards”) were issued, whose vesting is dependent upon future events that were not deemed probable of occurring at the time of grant through March 31, 2025. The exercise price of the Performance Awards will be equal to the closing price per share of the Company’s common stock on the trading day preceding the vesting date. Due to the variability in the exercise price of the Performance Awards, that is the exercise price will be equal to the closing price per share on the date preceding the vesting date, the Company concluded that the grant date was not established for accounting purposes. The fair value of the Performance Awards on the date of award was $671,250. As of September 30, 2025, the fair value of the Performance Awards was $1,287,000. The Company did not recognize compensation expense for such awards as the grant date has not been established nor is the achievement of the milestone considered probable. The Company will reassess the probability of achievement at each reporting date and will recognize compensation expense if and when the performance condition becomes probable of achievement.

The weighted-average grant date fair value per share of options granted during the six months ended September 30, 2025 was $1.38.

Due to the variability of the exercise price, which will be equal to the closing price per share of the Company’s common stock on the trading day preceding the vesting date, the Company uses a Monte Carlo simulation model to estimate the fair value of Performance Awards. In applying the Monte Carlo simulation model, the Company used the following assumptions in the valuation of the Performance Awards as of September 30, 2025:

SCHEDULE OF FAIR VALUE OF STOCK OPTIONS

Exercise price	Variable
Contractual term (years)		9.13
Volatility (annual)		72	%
Risk-free rate		4.0	%
Dividend yield (per share)		0	%

Equity issued for consulting services

Unrelated to the Plan, the Company issued 30,000 shares of Common Stock to a third party for consulting services, which were valued at $138,979 and recorded as stock-based compensation expense for the three months ended June 30, 2024.

NOTE 10 - GOODWILL AND INTANGIBLE ASSETS

Orocidin A/S

On May 13, 2024, the Company and certain shareholders of Orocidin A/S, a Danish stock corporation entered into a Stock Purchase and Sale Agreement (“Business Combination”), under which the Company issued 3,800,000 restricted shares of its Common Stock to the Sellers in exchange for 95% of Orocidin’s outstanding shares of capital stock. The shares were valued at $5.00, the closing stock price of the Company on the date of acquisition.

Orocidin A/S is a preclinical-stage biotechnology company, and is developing a proprietary first-of-its-kind medical treatment for aggressive periodontitis.

The Company accounted for the transaction as a business combination under ASC 805 and as a result, allocated the fair value of identifiable assets acquired and liabilities assumed as of the acquisition date. The excess of the purchase price over the estimated fair values of the underlying identifiable assets acquired, liabilities assumed was allocated to goodwill.

The $15,680,760 of acquired intangible assets was assigned to IPR&D assets that was recognized at fair value on the acquisition date. To value the IPR&D, the Company utilized the Multi-Period Excess Earnings Method (“MPEEM”), under the Income Approach. The method considers the present value of excess earnings generated by Orocidin’s IPR&D after taking into account the cost to realize the revenue, charges for contributory assets and an appropriate discount rate to reflect the time value and risk associated with the invested capital. IPR&D acquired represents Orocidin’s research and development activities related to its next generation of periodontitis therapies.

On November 11, 2024, the Company acquired the remaining 29,663 outstanding common shares and voting interest, or 5.34%, of Orocidin. The acquisition-date fair value of the consideration transferred totaled $650,000, which consisted of 200,000 shares of the Company’s Common Stock. The fair value of the 200,000 common shares issued was determined based on the closing market price of the Company’s Common Stock on the acquisition date, $3.25.

Bio-Convert A/S

On November 11, 2024 (the acquisition date), the Company acquired 100% of the outstanding common shares and voting interest of Bio-Convert A/S (“Bio-Convert”). The Company accounted for the transaction as a business combination under ASC 805.

Bio-Convert is a Denmark-based preclinical-stage biotechnology company focused on revolutionizing the treatment of oral leukoplakia, which is a potentially malignant disorder affecting the oral mucosa. Oral leukoplakia is a white patch or plaque that can develop in the oral cavity and when accompanied by dysplasia, it becomes a marker of disease progression and patients can potentially develop oral cancer. Bio-Convert is developing a new pharmaceutical drug product for the treatment of oral leukoplakia and the prevention of oral cancer formation. This is achieved through a proprietary mucoadhesive oral topical formulation that delivers the drug without any systemic absorption. The aim of the treatment is therefore to eliminate the lesions or to reduce the malignant conversion rate of oral leukoplakia to oral cancer. The effect on oral cancer may improve the surgical removal procedure should this be needed for the oral cancer patients. Bio-Convert’s current plan is to conduct a pilot efficacy study in patients with oral leukoplakia.

The acquisition-date fair value of the consideration transferred totaled $39,000,000, which consisted of 12,000,000 shares of the Company’s Common Stock. The fair value of the 12,000,000 common shares issued was determined based on the closing market price of the Company’s Common Stock on the acquisition date, $3.25.

The $26,675,670 of acquired intangible assets was assigned to in-process research and development assets that was recognized at fair value on the acquisition date. To value the IPR&D, the Company utilized the Multi-Period Excess Earnings Method (“MPEEM”), under the Income Approach. The method considers the present value of excess earnings generated by Bio-Covert’s IPR&D after taking into account the cost to realize the revenue, charges for contributory assets and an appropriate discount rate to reflect the time value and risk associated with the invested capital. IPR&D acquired represents Bio-Convert’s research and development activities related to its new pharmaceutical drug product for the treatment of oral leukoplakia and the prevention of oral cancer formation.

The following table summarizes the goodwill activity for six months ended September 30, 2025:

SCHEDULE OF GOODWILL

	Orocidin		Bio-Convert		Total
Balance as of March 31, 2025	$	7,084,829	$	18,405,922	$	25,490,751
Foreign currency translation adjustment		612,930		1,592,349		2,205,279
Balance as of September 30, 2025	$	7,697,759	$	19,998,271	$	27,696,030

The following table summarizes the in-process research and development activity for the six months ended September 30, 2025:

	Orocidin		Bio-Convert		Total
Balance as of March 31, 2025	$	15,679,626	$	27,028,453	$	42,708,079
Foreign currency translation adjustment		1,356,490		2,338,311		3,694,801
Balance as of September 30, 2025	$	17,036,116	$	29,366,764	$	46,402,880

NOTE 11 - WARRANTS

A summary of the Company’s outstanding warrant activity for six months ended September 30, 2025 is as follows:

SCHEDULE OF WARRANT ACTIVITIES

			Weighted		Weighted
			Average		Average
	Number of		Exercise		Remaining Contract
	Warrants		Price		Term
Outstanding, March 31, 2025		75,000	$	10.00		2.75
Issued		—		—		—
Expired/cancelled		—		—		—
Exercised		—		—		—
Outstanding, September 30, 2025		75,000	$	10.00		2.25

All of the outstanding warrants are exercisable as of September 30, 2025 with an intrinsic value of $0.

NOTE 12 - SEGMENT REPORTING

The Company operates as a single operating segment, which consists of the Company’s wholly-owned subsidiaries, Orocidin and Bio-Convert, both of which are focused on developing medicines supporting oral health. The Company has one reportable segment, which consists of its single operating segment.

The accounting policies of the segment are the same as those described in the summary of significant accounting policies.

The Company’s Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). When evaluating the Company’s financial performance and deciding how to allocate resources, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company-wide basis. The Company’s CODM uses net loss to evaluate past spending and to guide decisions of future spending. Net loss is used to monitor budget versus actual results.

The Company did not generate any revenue during the three and six months ended September 30, 2025. The Company has no material intra-entity revenues or expenses. As the Company is currently in the pre-revenue phase, the aforementioned operating expenses are the primary drivers that guide decisions of future spending and to monitor performance.

The measure of segment assets is reported on the balance sheet as total assets.

The CODM does not separately evaluate performance by geographic region or product line, as the Company has not yet commenced commercial operations and has limited operations due to the current liquidity and funding of the Company. The Company’s operations are conducted within the United States of America and Denmark.

NOTE 13 - SUBSEQUENT EVENTS

Management has evaluated subsequent events from the balance sheet date through the date the financial statements were available to be issued and has determined that no material subsequent events exist other than the following:

On October 1, 2025, the Company entered into a consulting agreement with Darlington Group, LLC (“Darlington Group”), which is controlled by Andrew Ritter, a member of the Company’s board of directors. Darlington Group will provide consulting services concerning strategic guidance on U.S. capital markets and drug development; market access and network development; partnerships, industry intelligence and strategic planning; and operational support. The agreement is terminable by either party on 30 days’ advance notice. For these services, Darlington Group will be paid $10,000 in advance per quarter on each October 1, January 1, April 1 and July 1 during the term of the agreement, commencing October 1, 2025.

On October 1, 2025, the Company repurchased 57,642 shares of Common Stock from an existing shareholder for $1.36 per share. The repurchase was made pursuant to the share repurchase program authorized by the Company’s Board of Directors (See Note 8). Following the transaction, 142,358 shares remain authorized for repurchase.

On October 1, 2025, the Company established a subsidiary, NoviThera ApS, to research and develop a novel monoclonal antibody therapy for the treatment of psoriasis. Upon formation, the Company acquired a 50.01% ownership interest in NoviThera ApS.

In October 2025, the Company issued to certain private investors a total of 225,000 restricted shares of its common stock, par value $0.001 per share. The price per share was $2.75 for gross proceeds of $618,750.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

The information in this report contains forward-looking statements. All statements other than statements of historical fact made in this report are forward-looking. In particular, the statements herein regarding industry prospects and future results of operations or financial position are forward-looking statements. These forward-looking statements can be identified by the use of words such as “believes,” “estimates,” “could,” “possibly,” “probably,” anticipates,” “projects,” “expects,” “may,” “will,” or “should” or other variations or similar words. No assurances can be given that the future results anticipated by the forward-looking statements will be achieved. Forward-looking statements reflect management’s current expectations and are inherently uncertain. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, our actual results may differ significantly from management’s expectations. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those anticipated in these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q or, in the case of documents referred to or incorporated by reference, the date of those documents.

The following discussion and analysis should be read in conjunction with our unaudited financial statements, included herewith. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management.

Overview

Nordicus Partners Corporation is a U.S. publicly listed business accelerator and holding company dedicated to helping Nordic life sciences companies succeed in the American market. By combining Nordic innovation with U.S. operational expertise, Nordicus Partners Corporation creates a distinct advantage in identifying, scaling, and exiting high-potential companies in fast-growing markets with unmet medical needs. Current portfolio companies include the two promising preclinical biotechnology companies Orocidin A/S and Bio-Convert A/S.

Organizational History

We were founded in 1993 and in 2007 were reincorporated from a Massachusetts corporation to a Delaware corporation. We changed our name from CardioTech International, Inc. to AdvanSource Biomaterials Corporation, effective October 15, 2008. On March 3, 2020, we changed our name to EKIMAS Corporation.

On October 12, 2021, we entered into a Stock Purchase Agreement (the “SPA”) with Reddington Partners LLC, a California limited liability company(“Reddington”) providing for the purchase of a total of 5,114,475 shares of our common stock, on a post-split basis, or approximately 90% of our total shares of common stock outstanding for total cash consideration of $400,000. Reddington purchased the common stock in two tranches on October 12, 2021 (the “First Closing”) and March 15, 2022.

Pursuant to the SPA, the Company effectuated a 1-for-50 reverse stock split on March 11, 2022 (the “Reverse Split”). Accordingly, on a post-split basis, the shares purchased in connection with the First Closing resulted in Reddington owning 42,273 shares of our common stock. As set forth in the SPA, Reddington then purchased from us on March 15, 2022, an additional 469,175 shares of our common stock, on a post-split basis (the “Second Closing”). After the issuance thereof Reddington owned 511,448 shares of our common stock, or approximately 90% of our total shares of common stock outstanding.

On February 23, 2023, Tom Glaesner Larsen and Christian Hill-Madsen were appointed directors of the Company.

On May 17, 2023, the Company changed its name to Nordicus Partners Corporation and its ticker symbol to NORD.

On June 1, 2023, the Company acquired a 4.99% interest in Mag Mile Capital, Inc., a full-service commercial real estate mortgage banking firm headquartered in Chicago with offices in the states of New York, Massachusetts, Connecticut, Florida, Texas and Nevada. Mag Mile Capital is a national platform comprised of capital markets specialists with extensive experience in real estate bridge financing, mezzanine and permanent debt placement and equity arrangements throughout the full capital stack and across all major real estate asset classes nationwide, including hotels, multifamily, office, retail, industrial, healthcare, self-storage and special purpose properties, offering access to structured debt and equity advisory solutions and placement for real estate investors, developers, and entrepreneurs.

On June 9, 2023, Mr. Tom Glaesner Larsen resigned as a director of the Company and Henrik Keller was appointed as his replacement.

On May 13, 2024, the Company and certain shareholders of Orocidin A/S (the “Orocidin Sellers”), a Danish stock corporation (“Orocidin”) entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Orocidin Sellers sold to the Company 525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing 95.0% of Orocidin’s outstanding shares of capital stock. In exchange, the Company issued 3,800,000 restricted shares of its common stock to the Orocidin Sellers. The transaction was consummated on May 13, 2024. Orocidin A/S, is a preclinical-stage biotechnology company which is advancing the next generation of periodontitis therapies.

On June 3, 2024, Mr. Christian Hill-Madsen resigned as a director of the Company and Peter Severin was appointed as his replacement.

On November 8, 2024, the Company effectuated a 1-for-10 reverse stock split of its issued and outstanding common stock, rounding up to account for any fractional shares (the “Reverse Stock Split”). The Reverse Stock Split had no effect on the Company’s authorized shares of common stock or preferred stock and the par value will remain unchanged at $0.001, respectively. All common stock share, option, warrant and per share amounts (except our authorized but unissued shares) have been retroactively adjusted in these unaudited consolidated financial statements and related disclosures.

On November 11, 2024, the Company announced that it entered into an agreement with Bio-Convert A/S (“Bio-Convert”) to acquire 100% of the outstanding shares of Bio-Convert in exchange for 12,000,000 restricted shares of the Company’s common stock. Bio-Convert is a Denmark-based preclinical-stage biotechnology company aiming to revolutionize the treatment of oral leukoplakia by minimizing or removing oral leukoplakia lesions in order to further reduce the risk of such lesions resulting in the development of oral cancer in patients.

On November 12, 2024, the Company entered into an agreement with Orocidin A/S to acquire the remaining 29,663 outstanding shares, or approximately 5%, of Orocidin A/S. In exchange, the Company issued 200,000 shares of restricted common stock to the selling shareholders of Orocidin. Upon closing of the acquisition, Orocidin A/S became a 100% wholly owned subsidiary of the Company.

In October 2005, the Company formed a new subsidiary named NoviThera ApS, with the objective to research and develop a novel and unique Monoclonal antibody (MaB) as a novel innovative therapy for the treatment of psoriasis. The invention was made by Alteral Therapeutics in Denmark and the drug development acquired by NoviThera. Mr. Allan Wehnert, who controls Alteral Therapeutics, was appointed CEO of NoviThera.

Our Business

Since the current leadership assumed control of Nordicus Partners Corporation (“Nordicus” or the “Company”), the Company has evolved into a leading U.S. publicly listed business accelerator and holding company dedicated to helping Nordic life sciences companies succeed in the American market. By combining Nordic innovation with U.S. operational expertise, Nordicus Partners Corporation creates a distinct advantage in identifying, scaling, and exiting high-potential companies in fast-growing markets with unmet medical needs.

Nordicus’ mission is to back high-growth ventures and transformative innovations in the life sciences sector. By providing capital, strategic guidance, and operational resources, we unlock each company’s potential to generate significant value and drive robust financial returns. Our hands-on approach—engaging, empowering, and capitalizing our portfolio companies—actively propels their success.

Our approach blends strategic counsel, operational know-how, and the cultivation of meaningful partnerships. This integrated support strengthens our companies’ market positions and helps them achieve their growth ambitions. Drawing on the combined expertise of our skilled Nordic and U.S. teams, we deliver a unique perspective that advances each portfolio company toward its full potential.

Nordicus’ portfolio diversification strategy positions us as a stable and resilient company, mitigating risk with significant upside potential.

Our Approach and Value Creation Process

Nordicus employs a 4-step value creation process:

	–	Scout and Accelerate: Nordicus targets high-impact potential companies, providing capital, resources and expertise to drive critical milestones such as patent filings and clinical trials.

	–	Acquire and Exit: Nordicus acquires controlling stakes to maximize value creation and exit at premium multiples.

We scout the Nordic region looking for early-stage life sciences companies developing drugs or treatments for diseases in high growth markets with significant unmet medical needs, all in potential multibillion USD markets.

After a vigorous due diligence process, the chosen companies will be offered to join Nordicus’ accelerator program. Once the chosen companies have become accelerator clients, Nordicus takes an active role in advising the management team, assisting with strengthening the companies’ Board of Directors and establishing Advisory Boards including making introductions to strategic partners and talent.

Once the milestones – set by Nordicus – are met, Nordicus will typically offer to acquire the companies outright. The first three acquisitions will be all-stock transactions, with the first two acquisitions (Orocidin A/S and Bio-Convert A/S) having already been completed, fitting Nordicus’ criteria of inclusion.

Nordicus aims to take all portfolio companies’ drug developments through Phase I. Upon completion of Phase I, the following options will be considered:

	1.	Sale or merger of the portfolio company.
	2.	Further development through the next clinical phases.
	3.	Strategic partnership with a large pharmaceutical company that will invest in Nordicus for further drug development.
	4.	Stand-alone Initial Public Offering (IPO).

Nordicus’ current life sciences portfolio consists of three promising preclinical biotechnology companies in Orocidin A/S, Bio-Convert A/S, and NoviThera ApS, all of which are led by the accomplished pharmacologist, Allan Wehnert, who serves as CEO of both companies. Orocidin A/S and Bio-Convert A/S were acquired during the fiscal year ended March 31, 2025, and NoviThera ApS was formed in October 2025.

Orocidin A/S is developing a proprietary first-of-its-kind medical treatment for aggressive periodontitis. Bio-Convert A/S is focused on a treatment against oral leukoplakia (OLK) – an oral potentially malignant disorder – by developing a novel proprietary mucoadhesive oral topical formulation designed to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia.

NoviThera ApS was formed with the objective to research and develop a novel and unique Monoclonal antibody for the treatment of psoriasis.

Orocidin A/S latest development

Orocidin A/S has successfully completed a 14-day toxicology study in hamsters and a test of effectiveness in a Beagle Dog Study, respectively.

In the 14-days toxicology study, all animals exhibited high tolerance to the drug, with no adverse reactions and irritation at the buccal application site. No significant side effects were observed and more importantly, the necroscopic cross examination showed no changes in tissues. The successful completion of this study marks an important milestone for Orocidin A/S, providing the foundation for the upcoming pivotal 8-week toxicity study.

The Beagle Dog Study is the first study that shows Orocidin A/S drug, QR-01, having a direct effect on periodontitis diagnosed beagle dogs. The 13-day small efficacy study was conducted on beagle dogs with clinically confirmed periodontitis. The dogs demonstrated consistent improvements across key clinical endpoints, including the Gingival Index, the Plaque Index and overall periodontal Disease.

Moreover, QR-01 was well tolerated, with no adverse side effects reported throughout the treatment period. This represents a significant milestone for Orocidin’s lead product, QR-01, and strengthens Nordicus’ and Orocidin’s confidence as Orocidin prepare for the upcoming human pilot efficacy study.

Bio-Convert A/S latest development

Bio-Convert has received positive and constructive scientific advice from the Danish Medicines Agency (DKMA) regarding QR-02 as a treatment for oral leukoplakia. DKMA’s feedback paves the way toward a First in Human trial, with a high likelihood of animal studies rendered dispensable for the proposed formulation and route of application.

NoviThera ApS latest development

Formed in October 2025 with intellectual property invented by Alteral Therapeutics, NoviThera ApS is developing a novel anti Monoclonal antibody treatment to cure or prevent the occurrence of psoriasis, an immune-medicated inflammatory disease that causes keratinocyte hyperproliferation and inflammation. The key focus is to develop a human rat model that selectively will express the endogenous pathological peptides and to test this in other relevant animal disease models.

Results of Operations

Three Months Ended September 30, 2025 Compared to the Three Months Ended September 30, 2024

Operating Expenses

During the three months ended September 30, 2025, we had officer compensation expense of $285,398 compared to $49,104 for the three months ended September 30, 2024, an increase of $236,294 or 481%. This increase was primarily due to an increase in salaries for the Company’s chief executive officer and chief financial officer as well as stock-based compensation for board members added within the quarter. See Note 5 and 9 to our accompanying unaudited condensed consolidated financial statements for more information on these transactions.

For the three months ended September 30, 2025, we had professional fees of $119,192 compared to $46,428 for the three months ended September 30, 2024, an increase of $72,764 or 157%. The increase is largely due to increased legal and accounting expenses related to the acquisitions of Orocidin and Bio-Convert.

For the three months ended September 30, 2025, we had consulting expense of $3,160 compared to no expense for the three months ended September 30, 2024, a increase of $3,160 or 100%. The increase is due to fees paid to a board member of Nordicus for consulting services rendered during the three months ended September 30, 2025 that did not occur during the three months ended September 30, 2024.

For the three months ended September 30, 2025, we had general and administrative expenses (“G&A”) of $349,027 compared to $71,154 for the three months ended September 30, 2024, an increase of $277,873 or 391%. The increase in G&A expense is attributable to increased travel expenses as well as increased investor relation expenses. In addition, there was an increase in costs related to directors and officers insurance resulting from the expansion of the business.

For the three months ended September 30, 2025, we had research and development expense of $454,701 compared to $343,209 for the three months ended September 30, 2024, a decrease of $111,492 or 32%. The decrease is due to reduced research and development costs incurred by Orocidin.

Other (Expense) Income

For the three months ended September 30, 2025, we recorded a loss of $299,996 compared to $1 for the three months ended September 30, 2024 due to changes in fair value of investments for the three months ended September 30, 2024.

Other Comprehensive Income (Loss)

For the three months ended September 30, 2025, we recorded a loss of $228,975 on foreign currency translation adjustments compared to a gain of $16,771 for the three months ended September 30, 2024. The decrease is primarily driven by a higher volume of intangible assets denominated in Danish Krone and fluctuations in foreign exchange rates.

Six Months Ended September 30, 2025 Compared to the Six Months Ended September 30, 2024

Operating Expenses

During the six months ended September 30, 2025, we had officer compensation expense of $350,752 compared to $98,546 for the six months ended September 30, 2024, an increase of $252,206 or 256%. This increase was primarily due to an increase in salaries for the Company’s chief executive officer, chief financial officer, and board of directors fees. See Note 5 to our accompanying unaudited condensed consolidated financial statements for more information on these transactions.

For the six months ended September 30, 2025, we had professional fees of $396,963 compared to $72,210 for the six months ended September 30, 2024, an increase of $324,753 or 450%. The increase is largely due to increased legal and accounting expenses related to the acquisitions of Orocidin and Bio-Convert.

For the six months ended September 30, 2025, we had $3,160 of consulting expense compared to $150,000 for the six months ended September 30, 2024, a decrease of $146,840 or 98%. The decrease is due to fees paid to new members of Orocidin’s advisory board as well as the issuance of Common Stock to third parties as compensation for consulting services rendered during the six months ended September 30, 2024 that did not occur during the six months ended September 30, 2025.

For the six months ended September 30, 2025, we had G&A expense of $414,139 compared to $104,099 for the six months ended September 30, 2024, an increase of $310,040 or 298%. The increase in G&A expense is attributable to increased travel expenses as well as increased investor relation expenses. In addition, there was an increase in costs related to directors and officers insurance resulting from the expansion of the business.

For the six months ended September 30, 2025, we had research and development expense of $878,350 compared to $343,209 for the six months ended September 30, 2024, an increase of $535,141 or 156%. The increase is primarily due to research and development costs incurred by Bio-Convert which was not acquired until November 2024.

Other (Expense) Income

For the six months ended September 30, 2025, we recorded a loss of $674,996 of other expense compared to $1 for the six months ended September 30, 2024 due to changes in fair value of investments for the six months ended September 30, 2024.

Other Comprehensive Income (Loss)

For the six months ended September 30, 2025, we recorded a gain of $4,963,655 on foreign currency translation adjustments compared to a gain of $16,541 for the six months ended September 30, 2024. The increase is primarily driven by a higher volume of intangible assets denominated in Danish Krone and fluctuations in foreign exchange rates.

Liquidity and Capital Resources

In August 2025, our Board of Directors authorized a share repurchase program which permits us to repurchase up to an aggregate of 200,000 shares of our Common Stock from existing shareholders only, solely in privately negotiated transactions, at a purchase price per share not greater than the then-current market price as determined based on the last reported sale price of our Common Stock on our principal trading market. We are not obligated to repurchase any shares and may suspend or terminate the program at any time. Repurchased shares may be held as treasury stock or retired, as determined by management. The repurchase program will remain in effect until the earliest of (i) the repurchase of 200,000 shares, (ii) 12 months from the date the program was authorized, or (iii) revocation by further Board action. As of September 30, 2025, no share repurchases had closed.

During the six months ended September 30, 2025, we used $2,188,401 in operating activities compared to $599,871 used in operating activities during the six months ended September 30, 2024. This increase is primarily due to the significant increase in operating expenses incurred, as detailed in the preceding section, partially offset by net noncash operating activity of $812,759 and increases in prepaid expenses and other current assets of $374,059.

During the six months ended September 30, 2025, we had net cash used in investing activities of $10,844 compared to $132,198 provided by investing activities during the six months ended September 30, 2024. The cash used in investing activities during the six months ended September 30, 2025 was used to purchase plant, property, and equipment. This cash provided by investing activities during the six months ended September 30, 2024 resulted from cash acquired in the acquisitions of Orocidin.

During the six months ended September 30, 2025, we received $2,419,220 from financing activities primarily related to issuance of common stock. During the six months ended September 30, 2024, we received $447,330 from financing activities from proceeds from the issuance of common stock and the exercise of warrants.

Critical Accounting Estimates

Our management’s discussion and analysis of our financial condition and results of our operations is based on our unaudited condensed consolidated financial statements and accompanying notes, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Certain amounts included in or affecting the unaudited condensed consolidated financial statements presented in this Form 10-Q and related disclosure must be estimated, requiring management to make assumptions with respect to values or conditions which cannot be known with certainty at the time the unaudited condensed consolidated financial statements are prepared. Management believes that the accounting policies set forth below comprise the most important “critical accounting estimates” for the Company. Management evaluates such estimates on an ongoing basis, based upon historical results and experience, consultation with experts and other methods that management considers reasonable in the particular circumstances under which the judgments and estimates are made, as well as management’s forecasts as to the manner in which such circumstances may change in the future.

Indefinite-lived Intangible Assets

We account for indefinite-lived intangible assets in accordance with ASC Topic 350, Intangibles - Goodwill and Other (“ASC 350”). Indefinite-lived intangible assets (e.g. IPR&D), are not amortized but instead are reviewed for impairment annually, or more frequently if an event occurs or circumstances change which indicate that an asset might be impaired. Pursuant to ASC 350, we test indefinite-lived intangible assets for impairment by comparing their fair values to their carrying values. An impairment charge is recorded if the estimated fair value of such assets has decreased below their carrying values.

Fair Value of Financial Instruments

We follow paragraph 825-10-50-10 of the FASB ASC for disclosures about fair value of our financial instruments and paragraph 820-10-35-37 of the FASB ASC (“Paragraph 820-10-35-37”) to measure the fair value of our financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:

Level 1:	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
Level 2:	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
Level 3:	Pricing inputs that are generally unobservable inputs and not corroborated by market data.

Business Combinations

We account for business combinations under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations, where the total purchase price is allocated to the tangible and identified intangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The purchase price is allocated using the information currently available, and may be adjusted, up to one year from acquisition date, after obtaining more information regarding, among other things, asset valuations, liabilities assumed and revisions to preliminary estimates. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill. Identifiable intangible assets with finite lives are amortized over their useful lives. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which the costs are incurred. The results of operations of acquired businesses are included in the unaudited condensed consolidated financial statements from the acquisition date.

Goodwill

We assess goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. We regularly monitor current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing our annual goodwill impairment test, we are permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of any of our reporting units is less than its carrying amount, including goodwill. In performing the qualitative assessment, we consider certain events and circumstances specific to the reporting unit and the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of any of the reporting units is less than its carrying amount. We are also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If we choose to undertake the qualitative assessment and conclude that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, we would then proceed to the quantitative impairment test. In the quantitative assessment, we compare the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded. We assess goodwill for impairment on an annual basis as of March 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired.

Off-Balance Sheet Arrangements

As of September 30, 2025, we did not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Item 4. Controls and Procedures

Our chief executive and financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2025, using the Internal Control - Integrated Framework (2013) developed by the Committee of Sponsoring Organizations of the Treadway Commission. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its chief executive officer and chief financial officer, as appropriate, to allow timely decisions to be made regarding required disclosure. It should be noted that any system of controls and procedures, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met and that management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our chief executive and financial officer concluded that our disclosure controls and procedures as of September 30, 2025, were not effective at the reasonable assurance level due to limited resources in the finance and accounting functions. We intend to take appropriate and reasonable steps to make improvements to remediate these deficiencies.

Changes in Internal Control Over Financial Reporting

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) under the Exchange Act) during the fiscal period to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II. OTHER INFORMATION

Item 1. Legal Proceedings

We are not the subject of any pending legal proceedings; and to the knowledge of management, no proceedings are presently contemplated against us by any federal, state or local governmental agency. Further, to the knowledge of management, no director or executive officer is party to any action in which any has an interest adverse to us.

Item 1A. Risk Factors

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit No.		Description
31.1		Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of the Principal Financial and Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
10.1		Directors Agreement, dated as of August 7, 2025, between the Company and Torben Jensen. (1)
10.2		Directors Agreement, dated as of August 7, 2025, between the Company and Kim T. Mücke. (2)
10.3		Directors Agreement, dated as of August 7, 2025, between the Company and Andrew J. Ritter. (3)
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxomony Extension Calculation Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

(1)	Previously filed as Exhibit 10.1 to Form 8-K filed with the Commission on August 7, 2025.
(2)	Previously filed as Exhibit 10.2 to Form 8-K filed with the Commission on August 7, 2025.
(3)	Previously filed as Exhibit 10.3 to Form 8-K filed with the Commission on August 7, 2025.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 14, 2025	Nordicus Partners Corporation

	By	/s/ Henrik Rouf
		Henrik Rouf
		Chief Executive Officer and Principal Executive

	By	/s/ Bennett J. Yankowitz
		Bennett J. Yankowitz
		Director, Chief Financial Officer
		Principal Financial and Accounting Officer

Nordicus Partners Corp 10-Q